Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients.

ABSTRACT:

Background

Type 2 diabetes mellitus (T2DM) is a metabolic disorder in which the patients with high blood sugar develop insufficient insulin secretion or insulin resistance. The solute carrier family, 5 member 2 (SLC5A2) gene is a member of sodium/glucose transporter family which can reduce heart and kidney problems. The current study aims to look into any association between rs11646054 variant in SLC5A2 gene and the anti-diabetic efficacy and safety of empagliflozin.

Methods

14 T2DM who failed to respond to previous treatments, empagliflozin 10 mg was added for 6 months. Genotyping of the rs11646054 variant of SLC5A2 gene was performed by polymerase chain reaction (PCR) followed by Sanger sequencing.

Results

Although hemoglobin A1c (

SUBMITTER: Jamalizadeh M 

PROVIDER: S-EPMC8630276 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature